Blog

Feb 27, 2024, 8:12 PM
AcuraStem CEO, Sam Alworth, will present on the company's trailblazing approach to amyotrophic lateral sclerosis (ALS) therapies at the MDA Clinical & Scientific Conference on March 4th.
Feb 27, 2024, 5:39 PM
AcuraStem’s Head of Target Validation, Dr. Wen-Hsuan Chang, presented an update on the company's innovative UNC13A program at the 14th Annual California ALS Research Summit on January 19, 2024
Jan 30, 2024, 1:00 AM
AcuraStem Leverages iNeuroRx® Platform to Drive Innovative SYF2 and UNC13A Treatments Forward Toward Clinical Trial
Sep 25, 2023, 9:30 AM
Agreement enables the development of therapeutics, including AcuraStem’s AS-202 Candidate, an antisense oligonucleotide that suppresses levels of the PIKFYVE kinase
Jun 15, 2023, 7:11 PM
AcuraStem, a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases, is pleased to announce its sponsorship of the Gordon Research Seminar and Conference on "Amyotrophic Lateral Sclerosis (ALS) and Related Motor Neuron Diseases Mechanisms, Modeling and Translational Therapeutics."
May 29, 2023, 1:51 PM
Join AcuraStem's CEO, Sam Alworth, at the forthcoming 2023 BIO International Convention in Boston from June 5-8, 2023. AcuraStem is at the cutting edge of developing treatments for neurodegenerative diseases, including sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).
Apr 10, 2023, 3:13 PM
AcuraStem's CEO, Sam Alworth, is set to present on the company’s latest advances in the development of a PIKFYVE antisense oligonucleotide (ASO) therapeutic for diverse forms of FTD (FTD) at the Alzheimer's Drug Discovery Foundation's (ADDF) Defeating Dementia Symposium on April 13.
Mar 20, 2023, 8:30 PM
AcuraStem’s progress in advancing an antisense oligonucleotide (ASO) targeting PIKFYVE and development of therapeutic candidates targeting SYF2 in preclinical studies has been featured in a newly posted BioSpace article.
Mar 20, 2023, 1:54 PM
Fierce Biotech featured AcuraStem's pioneering work with PIKFYVE inhibitors in a recent article highlighting promising developments in treating both genetic and sporadic forms of ALS. The article discusses two recent studies led by Dr. Justin Ichida's lab at USC and the AcuraStem team that have identified drug candidates with potential to transform the disease course for a larger patient population beyond those with known genetic causes of ALS.
Mar 20, 2023, 12:32 AM
A recent study published in the journal Cell Stem Cell and co-authored by AcuraStem CEO Sam Alworth, M.S., MBA, and AcuraStem co-founder Justin Ichida, Ph.D., et al., shows that suppressing the gene encoding spliceosome-associated factor SYF2 may alleviate symptoms of Amyotrophic Lateral Sclerosis (ALS) and improve neuron survival in both sporadic and genetic forms of the disease.